Relay Therapeutics, Inc.
RLAY- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001812364
In the last 90 days, Relay Therapeutics, Inc. insiders filed 0 open-market purchases and 14 sales; 259 institutions reported holding it in 13F filings for Q2 2026, worth $4.58B in total; Duquesne Family Office is the only superinvestor holding it.
Holders of 5% or more of RLAY
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Relay Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Commodore Capital LP | 13G/A | 9.90%17.0M shares | +2.10 ppfrom 7.80% | May 15, 20253 filings | Nov 14, 2025 | SEC |
| Point72 Asset Management, L.P. | 13G/A | 7.80%13.4M shares | +2.10 ppfrom 5.70% | Mar 20, 20252 filings | Aug 14, 2025 | SEC |
| Casdin Capital, LLC | 13G/A | 7.50%13.0M shares | 0.00 ppfrom 7.50% | Feb 17, 20262 filings | Feb 17, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.10%10.3M shares | −2.70 ppfrom 8.80% | Feb 5, 20252 filings | Apr 17, 2025 | SEC |
| Perceptive Advisors LLC | 13G | 5.30%9.40M shares | New | Mar 19, 20261 filing | Mar 19, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
13 Schedule 13D and 13G filings on Relay Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 202611:34 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −5.47 ppfrom 5.47%Below 5% | Mar 13, 2026 | SEC |
| Mar 19, 20264:07 PM ET | Perceptive Advisors LLCand 2 others | 13G | 5.30%9.40M shares | New | Mar 12, 2026 | SEC |
| Feb 17, 20264:47 PM ET | Casdin Capital, LLCand 3 others | 13G/A | 7.50%13.0M shares | 0.00 ppfrom 7.50% | Dec 31, 2025 | SEC |
| Feb 17, 20264:45 PM ET | Casdin Capital, LLCand 3 others | 13G/A | 7.50%13.0M shares | – | Dec 31, 2025 | SEC |
| Nov 14, 20254:30 PM ET | Commodore Capital LPand 3 others | 13G/A | 9.90%17.0M shares | +2.10 ppfrom 7.80% | Sep 30, 2025 | SEC |
| Aug 14, 20255:07 PM ET | Commodore Capital LPand 3 others | 13G/A | 7.80%13.3M shares | +2.00 ppfrom 5.80% | Jun 30, 2025 | SEC |
| Aug 14, 20254:56 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 7.80%13.4M shares | +2.10 ppfrom 5.70% | Jun 30, 2025 | SEC |
| Jul 29, 20252:22 PM ET | Vanguard Group Inc | 13G/A | 5.47%9.38M shares | −1.67 ppfrom 7.14% | Jun 30, 2025 | SEC |
| May 15, 20254:05 PM ET | Commodore Capital LPand 1 other | 13G | 5.80%10.0M shares | New | May 8, 2025 | SEC |
| Apr 30, 202511:12 AM ET | Vanguard Group Inc | 13G/A | 7.14%12.1M shares | – | Mar 31, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 6.10%10.3M shares | −2.70 ppfrom 8.80% | Mar 31, 2025 | SEC |
| Mar 20, 20256:13 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 5.70%9.69M shares | New | Mar 14, 2025 | SEC |
| Feb 5, 20251:23 PM ET | BlackRock, Inc. | 13G/A | 8.80%14.7M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Relay Therapeutics, Inc. shares.
No Form 144 notices for Relay Therapeutics, Inc. are on file.